Treatment of Acute Leukemia Relapse After Allotransplantation
Treatment of Acute Leukemia Relapse After Allotransplantation
Patients with relapse of acute leukemia often only receive supportive therapy. Our hypothesis
 is that a combination therapy can stabilize the disease for patients with early relapse after
 allogeneic stem cell transplantation. The investigators will combine 5-azacitidine 100 mg
 daily subcutaneously (days 1-3), valproic acid (continuous therapy from day 1), All-trans
 retinoic acid (days 1-14) and hydroxurea (continuous treatment from day 15 of first cycle.
 Azacitidine and ATRA can be repeated with 5 weeks intervals, donor leukocyte infusions on day
 10 is allowed from the second cycle.
Inclusion Criteria:

 -  AML relapse within one year after transplantation

 -  Blood and marrow sampling being possible

 -  Expected survival at least 4 weeks

 -  No expected drug interactions

 -  Informed consent possible

 Exclusion Criteria:

 -  Intolerance to any study drug

 -  Serious kidney or liver disease

 -  Informed consent not possible

 -  Previous pancreatitis